Included in the formulation
АТХ:L.01.X.C.11 Ipilimumab
Pharmacodynamics:It binds to the cytotoxic antigen CTLA-4, located on the surface of T-lymphocytes and enhancing their activity, which leads to enhanced immunological responses to tumor cells.
Pharmacokinetics:After intravenous administration, the elimination half-life is 14.7 days.
Elimination by the kidneys.
Indications:It is used to treat metastatic or inoperable melanoma.
II.C43-C44 Melanoma and other malignant neoplasms of the skin
Contraindications:Acute infectious processes, pregnancy and lactation, age under 18, individual intolerance.
Carefully:Disorders of liver function, condition after transplantation, autoimmune diseases, Crohn's disease, hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - Category X. Contraindicated in pregnancy and lactation.
Dosing and Administration:Intravenously drip for 1.5 hours, 1 every 3 weeks for 3 mg / kg of weight in 100 ml of a solution of 0.9% sodium chloride or 5% dextrose. The course of treatment - 4 infusions.
The highest daily dose: 3 mg / kg.
The highest single dose: 3 mg / kg.
Side effects:Respiratory system: interstitial pneumonitis.
Hemopoietic system: hemolytic anemia.
The cardiovascular system: vasculitis, myocarditis, angiopathy.
Digestive system: pancreatitis.
Musculoskeletal system: arthritis.
Dermatological reactions: leukocytoclastic vasculitis, psoriasis.
Sense organs: blepharitis, iritis, conjunctivitis.
urinary system: glomerulonephritis.
Allergic reactions.
Overdose:Increased side effects.
Treatment is symptomatic.
Interaction:Clinically significant interactions are not described.
Special instructions:The drug is incompatible with other drugs in a single solution.